SCHEMBL2763533

SCHEMBL2763533

O=[N+]([O-])c1ccc(Oc2ccnc(NCCCO)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 3/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 2/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 4/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
HSPB1 P04792 1/20 0.39
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762537 0.83 KMT2A (0.46) TDP1PKMHPGDSMN1; SMN2LMNA
SCHEMBL2762483 0.83 MET (0.49) TDP1PKMHPGDSMN1; SMN2LMNA
SCHEMBL3187491 0.79 RAB9A (0.49) LMNARAB9AMAPTHTTALDH1A1
SCHEMBL2762297 0.76 KDR (0.52) HPGDSMN1; SMN2LMNAMAPTHTT
SCHEMBL2763083 0.73 KDR (0.52) RAB9ANPC1
SCHEMBL3176280 0.73 RAB9A (0.54) LMNARAB9AMAPTHTTALDH1A1
SCHEMBL4936375 0.72 ROCK1 (0.54) LMNARAB9AMAPTHTTALDH1A1
SCHEMBL2763413 0.71 HTT (0.50) SMN1; SMN2LMNARAB9AMAPTHTT
SCHEMBL9820311 0.69 ALDH1A1 (0.65) PKMHPGDSMN1; SMN2LMNAMAPT
SCHEMBL3835774 0.69 KMT2A (0.47) PKMHPGDSMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8080552-B2 Pyrimidyl derivatives as protein kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2011-12-20 US disclosed
EP-2102173-B1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2010-10-20 EP disclosed
US-20100041684-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-02-18 US disclosed
EP-2102173-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-09-23 EP disclosed
WO-2008077548-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041684-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, MAP4K2 TDP1 1507/4885PKM 218/4885HPGD 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.